How has your week started, myeloma world?

We hope it's going well so far.

We once again have a rather long list of new myeloma research we'd like to discuss with you. We sus­pect most of our readers will find at least one or two studies in the report to be of particular interest.

We begin today's report with a discussion of a somewhat rare eye-related side effect of Velcade (bor­tez­o­mib) and a possible way to control the side effect.

Next, we take a quick look at two articles about …

Good morning, myeloma world.

We hope your weekend has gotten off to a good start. We've been looking over the latest myeloma-related research since the last edition of Myeloma Morning, and it appears we have just a short list of new material to discuss today.

In fact, we will be focusing today on just two new research articles.

The first is from a team of U.S. researchers, most of whom are based at the Uni­versity of Arkansas for Medical Sciences (UAMS). The study looks at a novel way of …

Results of a recent small German study indicate that high cut-off hemodialysis combined with chemotherapy may help restore kidney function in multiple myeloma patients with a serious form of kidney failure called acute kidney injury.

In addition, the researchers found that myeloma patients were more likely to recover kidney function if they received treatment soon after their kidneys began to fail.

Based on these results, Dr. Katja Weisel, one of the study investigators from the University of Tübingen, recommends that patients with dialysis-dependent acute kidney injury be treated as soon as possible …

Research shows that approximately 20 percent of multiple myeloma patients develop kidney failure. Kidney failure occurs as a consequence of elevated calcium levels in the blood or when proteins called light chains are produced in excess - overloading the kidneys with protein.

Normally, the kidneys remove wastes, extra fluids, and minerals from the blood. But when they stop functioning, harmful wastes build up and this can cause other complications such as high blood pressure. Generally, kidney failure can worsen for multiple myeloma patients with fluid depletion, hypercalcemia, infection, nephrotoxic drugs (chemicals …

The results of a small-scale clinical study in England suggest that a new hemodialysis procedure may increase the lifespan of multiple myeloma patients suffering from kidney complications.

Kidney failure is a relatively common complication in multiple myeloma patients and can lead to life-threatening health issues. Hemodialysis clinically removes toxic waste substances from the blood, performing the same function as a healthy kidney.

Previous to this study, researchers had predicted that chemotherapy in combination with the new procedure, called high cutoff hemodialysis, might improve the condition of multiple myeloma patients. High cutoff dialysis …